Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 13/20 | 0.46 |
| ▸ | FADS1 | O60427 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL247568 | 0.99 | PTPN11 (0.45) | PTPN11FADS1PTGS1NPC1RAB9A | |
| SCHEMBL1473951 | 0.87 | NPC1 (0.54) | NPC1RAB9AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL3241440 | 0.87 | L3MBTL1 (0.47) | PTPN11FADS1PTGS1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL1471256 | 0.86 | NPC1 (0.53) | NPC1RAB9AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4089919 | 0.86 | RAB9A (0.50) | NPC1RAB9AALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4096059 | 0.85 | RAB9A (0.49) | NPC1RAB9AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4095632 | 0.85 | KMT2A (0.53) | NPC1RAB9AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL2063619 | 0.85 | ALKBH1 (0.50) | PTPN11NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL4089952 | 0.84 | KMT2A (0.52) | NPC1RAB9AALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2063475 | 0.84 | ALKBH1 (0.49) | PTPN11NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209783-B1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | ANIONA APS (DK) | 2016-03-16 | — | — | EP | disclosed |
| US-8343960-B2 | 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use | NEUROSEARCH A/S (DK) | 2013-01-01 | — | — | US | disclosed |
| US-20120004215-A1 | N-OXIDES OF DIAZABICYCLONONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| EP-2389380-A1 | N-OXIDES OF DIAZABICYCLONONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2011-11-30 | — | — | EP | disclosed |
| US-8041176-B2 | Cable exit trough with cover | ADC TELECOMMUNICATIONS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100298307-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2010-11-25 | — | — | US | disclosed |
| WO-2010084184-A1 | N-OXIDES OF DIAZABICYCLONONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298307-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | CHRNA6, CHRNA5, CHRNA2 | PTPN11 1698/4885FADS1 2761/4885PTGS1 744/4885 |
| US-20120004215-A1 | N-OXIDES OF DIAZABICYCLONONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | CHRNA5, CHRNA6, CHRNA10 | PTPN11 1687/4885FADS1 3098/4885PTGS1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.